文献速递产科母胎医学

对母胎医学会声明的警示性回应:妊娠期糖尿病的药物治疗

A cautionary response to SMFM statement: pharmacological treatment of gestational diabetes.
PubMed 文献 · Am J Obstet Gynecol · 2018-06-28

该文是对母胎医学会(SMFM)关于妊娠期糖尿病药物治疗推荐的警示性回应。作者指出二甲双胍可抑制胎儿生长、影响线粒体呼吸和表观遗传修饰,动物研究显示产前暴露对体重和代谢有不良长期结局,两项随机对照试验提示宫内暴露可能增加儿童期体重或肥胖。作者认为将二甲双胍等同于胰岛素或优于格列本脲为时过早。

要点

  • 二甲双胍胎儿浓度等于母体浓度,可抑制生长、抑制线粒体呼吸、改变表观遗传并模拟胎儿营养限制。
  • 动物研究显示产前二甲双胍暴露对体重和代谢有不良长期结局。
  • 两项随机对照试验提示宫内二甲双胍暴露可能产生增加儿童期体重或肥胖的代谢表型。

核心结论

  • 作者认为将二甲双胍等同于胰岛素或认为其优于格列本脲为时过早。
  • 作者同意美国糖尿病协会和美国妇产科医师学会推荐胰岛素为首选药物。
  • 作者呼吁开展精心对照的研究,根据口服药物在妊娠期的药效学和药代动力学特性优化剂量,根据个体高血糖模式选择药物,并对子代长期随访代谢风险。

研究设计与样本

  • 本文为针对母胎医学会(SMFM)声明的警示性回应文章。

主要发现

  • 二甲双胍胎儿浓度等于母体浓度。
  • 二甲双胍可抑制生长、抑制线粒体呼吸、对基因表达产生表观遗传修饰、模拟胎儿营养限制并改变出生后糖异生反应。
  • 胎盘和胎儿均表达二甲双胍转运体并表现出高线粒体活性。
  • 动物研究表明产前二甲双胍暴露对体重和代谢产生不良长期结局。
  • 两项近期针对妊娠期糖尿病或PCOS女性的临床随机对照试验提供证据表明宫内二甲双胍暴露可能产生增加儿童期体重或肥胖的代谢表型。

关键数值与推荐

  • 母胎医学会声明认为二甲双胍可作为妊娠期糖尿病治疗中胰岛素的安全一线替代,且优于格列本脲。
  • 美国糖尿病协会和美国妇产科医师学会推荐胰岛素为首选药物。
  • 直接比较二甲双胍与格列本脲的研究很少,尚不清楚二甲双胍单药是否优于格列本脲。
  • 既往临床研究中格列本脲的给药方式与其药代动力学特性不一致,导致血糖控制不佳和高母体低血糖发生率。

临床怎么用

  • 作者同意美国糖尿病协会和美国妇产科医师学会推荐胰岛素为首选药物。
  • 作者认为将二甲双胍等同于胰岛素或认为其优于格列本脲为时过早。
  • 作者呼吁开展精心对照的研究,根据口服药物在妊娠期的药效学和药代动力学特性优化剂量,根据个体高血糖模式选择药物,并对子代长期随访代谢风险。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Use of oral agents to treat gestational diabetes mellitus remains controversial. Recent recommendations from the Society for Maternal-Fetal Medicine assert that metformin may be a safe first-line alternative to insulin for gestational diabetes mellitus treatment and preferable to glyburide. However, several issues should give pause to the widespread adoption of metformin use during pregnancy. Fetal concentrations of metformin are equal to maternal, and metformin can inhibit growth, suppress mitochondrial respiration, have epigenetic modifications on gene expression, mimic fetal nutrient restriction, and alter postnatal gluconeogenic responses. Because both the placenta and fetus express metformin transporters and exhibit high mitochondrial activity, these properties raise important questions about developmental programming of metabolic disease in offspring. Animal studies have demonstrated that prenatal metformin exposure results in adverse long-term outcomes on body weight and metabolism. Two recent clinical randomized controlled trials in women with gestational diabetes mellitus or polycystic ovary syndrome provide evidence that metformin exposure in utero may produce a metabolic phenotype that increases childhood weight or obesity. These developmental programming effects challenge the conclusion that metformin is equivalent to insulin. Although the Society for Maternal-Fetal Medicine statement endorsed metformin over glyburide if oral agents are used, there are few studies directly comparing the 2 agents and it is not clear that metformin alone is superior to glyburide. Moreover, it should be noted that prior clinical studies have dosed glyburide in a manner inconsistent with its pharmacokinetic properties, resulting in poor glycemic control and high rates of maternal hypoglycemia. We concur with the American Diabetes Association and American Congress of Obstetricians and Gynecologists, which recommend insulin as the preferred agent, but we believe that it is premature to embrace metformin as equivalent to insulin or superior to glyburide. Due to the uncertainty of the long-term metabolic risks of either metformin or glyburide, we call for carefully controlled studies that optimize oral medication dosing according to their pharmacodynamic and pharmacokinetic properties in pregnancy, appropriately target medications based on individual patterns of hyperglycemia, and follow the offspring long-term for metabolic risk.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Barbour LA, Scifres C, Valent AM, et al. A cautionary response to SMFM statement: pharmacological treatment of gestational diabetes. Am J Obstet Gynecol. 2018. PMID: 29959933. doi:10.1016/j.ajog.2018.06.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。